美女免费一级视频在线观看
Supreme Group has acquired MM+M Rare Disease Agency of the Year finalist Pivot Design, marking Supreme Group’s ninth acquisition in the past 18 months.
Based in West Chester, PA and backed by Trinity Hunt Partners, Supreme debuted on MM+M’s Agency 100 at 57th with $46.5 million in revenue in 2024. Pivot also appeared on the A100 at 96th, growing its revenue 14% to roughly $18 million.
Pivot Design brings three decades of experience and aids Supreme in expanding its operations in the pharma and rare diseases spaces. Pivot has created omnichannel campaigns based in storytelling that work to drive real-world change within this sector.
“Pivot brings strong experience in brand strategy, in creative and in omnichannel capabilities and we’ve really just been able to double down on those three areas,” said Tom Donnelly, Supreme Group’s CEO.
Pivot’s strong presence in pharma strengthens Supreme’s portfolio of strong healthcare and life sciences agencies. It is an area that Donnelly explained can make a direct impact with clients.
Pivot will maintain its distinct brand identity and leadership while gaming access to inter-agency collaboration and enhanced capabilities through Supreme’s platforms. Conversely, Supreme has gained a team that has created breakthrough brand experiences from complex science.
The acquisition is part of Supreme’s broader goal to build a network of specialized agencies. Other acquisitions include Health+Commerce, Amendola, BioStrata, Curator24, Kadiko and more. Previously Supreme Group has described itself as a platform of connected agencies, threading the needle between a holding company and a loose collection of agencies.
“Every one of our acquisitions has been in service of our vision. Pivot really just doubles down on that,” Donnelly said.
Supreme Group counts Astellas (Xospata), AviadoBio, Azura Ophthalmics, Danaher, Enovis, Hikma Pharmaceuticals, Kaleidoscope Bio, Labcorp, RapidAI and Servier as clients.
Pivot Design had three significant launches that fueled its growth last year for Lantheus Link (a diagnostics support platform), United Therapeutics’ UT Cares (serving pulmonary hypertension patients) and a new program for Zevra Therapeutics’ Olpruva (for Niemann-Pick disease type C).
Supreme will continue to work with agencies that further its goals of leveraging AI, data, and technology to enhance marketing capabilities.